How do these autoantibodies affect neuronal signaling and cerebellar immunity?

Autoantibodies to neuronal surface proteins and Purkinje-cell antigens have different biological and diagnostic implications, but the overall claim is well supported. Surface-directed antibodies can directly alter neuronal signaling; defined Purkinje-cell antibodies more often identify a cerebellar-directed immune process and, for some specificities, an important paraneoplastic context.

Neuronal surface-signaling effects

• Glycine receptor α1 (GlyRα1) antibodies have particularly direct functional evidence. Patient antibodies bind extracellular receptor epitopes, trigger receptor internalization and lysosomal degradation, and can deposit C3b in vitro. Patient IgG rapidly reduces glycinergic synaptic currents in cultured motor neurons and lowers glycinergic event frequency in brainstem slices, consistent with impaired inhibitory neurotransmission.
• CASPR2 antibodies can inhibit the CASPR2–contactin-2 interaction. Experimental preparations have also reduced CASPR2 expression and potassium-channel currents in sensory neurons, with increased excitability and network activity reported in neuronal models. Effects differ among patient samples and IgG subclasses; disruption of contactin-2 binding can occur without measurable surface-CASPR2 loss.

Cerebellar immune targeting

• Defined Purkinje-cell antibodies—especially PCA-1/anti-Yo and Tr/DNER—strongly support cerebellar-directed autoimmunity when accompanied by a compatible subacute or rapidly progressive cerebellar syndrome.
• Anti-Yo is primarily a marker of a T-cell-predominant immune process rather than proof that circulating antibody itself causes Purkinje-cell injury. In one PCA-1-positive cohort, cancer was identified in 88% of patients; Tr/DNER is also associated with Hodgkin lymphoma.

Clinical implications

• Antibody results require antigen-specific confirmation and phenotype-aware interpretation. Serum/CSF compartment, titer, assay format, and isotype influence meaning; isolated low-level or discordant serum results should not be treated as diagnostic alone.
• Compatible high-risk Purkinje-cell antibody results warrant prompt tailored malignancy evaluation.

Bottom line

• GlyR and CASPR2 antibodies can disrupt neuronal surface signaling, while validated Purkinje-cell antibodies indicate cerebellar immune targeting—though neither an isolated antibody result nor a single mechanism alone establishes active disease in an individual patient.